As of 02 May 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of ticagrelor [90mg film-coated tablet] as an add-on to aspirin for adults with acute coronary syndrome (ACS) for possible financing by the Department of Health (DOH) and/or the Philippine Health Insurance Corporation (PhilHealth). The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from 02 May (Friday) to 19 May (Monday) 2025.

As a preliminary recommendation, the HTA Council does not recommend the government financing of ticagrelor [90mg film-coated tablet] as an add-on to aspirin for adults with ACS. This HTA Council preliminary recommendation draws from the evidentiary bases below.

For the supporting evidence reviewed and discussed by the HTA Council in coming up with this preliminary recommendation, please refer to: https://tinyurl.com/PrelimRecommTicagrelorACS. All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 19 May 2025 (Monday), for the consideration of the HTA Council, through email at hta@dost.gov.ph. Please use the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format, and those submitted beyond the deadline shall not be entertained.

Should you have any questions or concerns regarding the preliminary recommendation, please do not hesitate to contact us through the same email address or via telephone call at (02) 8837 2071 loc. 4100.